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Aims Various drugs increase the risk of out-of-hospital cardiac arrest (OHCA) in the general population by impacting cardiac
ion channels, thereby causing ventricular tachycardia/fibrillation (VT/VF). Dihydropyridines block L-type calcium channels,
but their association with OHCA risk is unknown. We aimed to study whether nifedipine and/or amlodipine, often-used




We conducted a case–control study with VT/VF-documented OHCA cases with presumed cardiac cause from on-
going population-based OHCA registries in the Netherlands and Denmark, and age/sex/index date-matched non-
OHCA controls (Netherlands: PHARMO Database Network, Denmark: Danish Civil Registration System). We
included 2503 OHCA cases, 10 543 non-OHCA controls in Netherlands, and 8101 OHCA cases, 40 505 non-
OHCA controls in Denmark. To examine drug effects on cardiac electrophysiology, we performed single-cell
patch-clamp studies in human-induced pluripotent stem cell-derived cardiomyocytes. Use of high-dose nifedipine
(>_60 mg/day), but not low-dose nifedipine (<60 mg/day) or amlodipine (any-dose), was associated with higher
OHCA risk than non-use of dihydropyridines [Netherlands: adjusted odds ratios (ORadj) 1.45 (95% confidence
interval 1.02–2.07), Denmark: 1.96 (1.18–3.25)] or use of amlodipine [Netherlands: 2.31 (1.54–3.47), Denmark:
2.20 (1.32–3.67)]. Out-of-hospital cardiac arrest risk of (high-dose) nifedipine use was not further increased in
patients using nitrates, or with a history of ischaemic heart disease. Nifedipine and amlodipine blocked L-type cal-
cium channels at similar concentrations, but, at clinically used concentrations, nifedipine caused more L-type cal-
cium current block, resulting in more action potential shortening.
...................................................................................................................................................................................................
Conclusion High-dose nifedipine, but not low-dose nifedipine or any-dose amlodipine, is associated with increased OHCA risk
in the general population. Careful titration of nifedipine dose should be considered.
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Sudden cardiac arrest causes up to 50% of all cardiovascular deaths in
industrialized countries1 and most often occurs in the general popula-
tion (out-of-hospital cardiac arrest, OHCA). OHCA predominantly
results from lethal cardiac arrhythmias [ventricular tachycardia/ven-
tricular fibrillation (VT/VF)] following disruptions in cardiac electro-
physiology.2 Numerous factors may cause such disruptions by
impacting cardiac ion channels. Many commonly prescribed drugs,
even those prescribed for non-cardiac disease, impact cardiac ion
channels and are associated with increased OHCA risk.3 The best-
known risk drugs are drugs that block cardiac potassium channels,
thereby impairing cardiac repolarization (QT-prolonging drugs).4–9
Emerging evidence also demonstrates the risk of non-cardiac
drugs that impair cardiac depolarization10 by blocking cardiac so-
dium-channels.3,11,12 The possible OHCA risk of another type of
depolarization-blocking drugs is less known: dihydropyridine calcium-
channel blocking drugs. Dihydropyridines block L-type calcium-
channels, primarily but not exclusively in vascular smooth muscle,13
and are generally prescribed to treat ischaemic heart disease (IHD)
or hypertension. Use of nifedipine has been associated with increased
risk of all-cause mortality.14 One proposed explanation was
increased sympathetic stimulation and catecholamine release.15
Although these changes may trigger VT/VF, it is unknown whether
this excess mortality resulted from OHCA.
In this study, we aimed to establish whether use of nifedipine or
amlodipine (the two most widely used dihydropyridines in the
Netherlands) is associated with increased OHCA risk. We per-
formed a case–control study in the Netherlands and a replication
case–control study in Denmark, using population-based emergency
medical services (EMS)-attended OHCA registries in both settings to
study whether these drugs are associated with increased OHCA risk.
We performed subgroup analyses to address confounding by
indication of IHD and/or use of beta-blocking drugs. In addition,
we assessed cellular electrophysiologic properties of nifedipine
and amlodipine, by performing single-cell patch-clamp studies in




We used a case–control design with OHCA cases from ongoing
population-based EMS-attended OHCA registries in the Netherlands
(Amsterdam REsuscitation STudies, ARREST) and Denmark (replication
cohort: Danish Cardiac Arrest Registry, DANCAR), and non-OHCA
controls (Netherlands: PHARMO Database Network, Denmark: general
population through the Danish Civil Registration System). Both OHCA
registries are part of the ESCAPE-NET consortium that studies OHCA
across Europe.16 Cases were OHCA victims aged >_18 years with docu-
mented VT/VF from presumed cardiac causes (excluding obvious non-
cardiac causes). For both registries, each case was matched using exact
matching on age at the date of OHCA (index-date), sex, and index-date
with up to five controls who were alive on the index-date.
The study was approved by the Institutional Review Boards of
the Academic Medical Center Amsterdam and the Danish Data
Protection Agency (Ref.no. 2007-58-0015, local ref.no. GEH-2014-017,
I-Suite.nr. 02735). In Denmark, ethical approval is not required for retro-
spective register-based studies in which individual patients cannot be
identified.
The Netherlands
ARREST registry is an ongoing population-based observational registry
that prospectively includes all OHCAs in one contiguous region of the
Netherlands (2.4 million inhabitants, urban, and rural). Details of this
registry are described elsewhere.17 In short, the ARREST study centre is
notified by the dispatch centre of every suspected OHCA in which EMS
are involved. ECGs are collected from automated external defibrillators
or EMS manual defibrillators, whichever defibrillated first. Complete
drug-dispensing records 1 year before index-date are obtained from the
community pharmacist. All OHCA cases from 1 June 2005 to 31
December 2011 were included. Non-OHCA controls were sampled
from PHARMO Database Network, which contains drug-dispensing
records from community pharmacies.18 In the Netherlands, nearly all
patients are registered at a single community pharmacy; therefore, medi-
cation records were considered complete.
Denmark
Out-of-hospital cardiac arrest cases were included in the DANCAR
registry if they had attempts of resuscitation by a bystander or EMS.
Capture of OHCA is nearly complete as the EMS are obliged to complete
a case report form for every attended OHCA. Information on the first
registered heart rhythm (shockable or non-shockable) was obtained
from these forms, which constitute the DANCAR registry. Details of this
registry are described elsewhere.19 All OHCA cases from 1 June 2001 to
31 December 2014 were included. A unique and permanent civil registra-
tion number is assigned to all Danish citizens upon birth or immigration.
This allows individual-level linkage of information between nationwide
registries in Denmark. Information on age, sex, and vital status were
obtained from the Danish Civil Registration System.20 Data on hospital
admissions were identified using the Danish National Patient Registry
(one primary diagnosis and two or more secondary diagnoses if appropri-
ate) according to the International Classification of Diseases (ICD); since
1994 the 10th revision (ICD-10) and before 1994 the 8th revision (ICD-
8).21 Causes of death according to the ICD classifications were deter-
mined using the National Causes of Death Registry.22 Information on
pharmacotherapy was obtained from The Danish Registry of Medicinal
Product Statistics, which includes all drug-dispensing records from
Danish pharmacies since 1995.23
Exposure definition
Current use was defined as a prescription starting in (ARREST) or cover-
ing (DANCAR) a period of maximally 90 days before the index-date. In
DANCAR, daily dosage was estimated by calculating mean dosages from
up to five consecutive prescriptions before the prescription of interest.
Treatment duration was calculated by dividing the number of tablets in
the prescription of interest by daily dosage, as described previously.24
Dose-response analyses were examined using the defined daily dose
(DDD, the recommended average maintenance daily dose for a medica-
tion used for its main indication).25 Drug use was defined as low-dose
(DDD < 2: nifedipine <60 mg/day, amlodipine <10 mg/day) or high-dose
(DDD >_ 2: nifedipine >_60 mg/day, amlodipine >_10 mg/day).
Covariates for out-of-hospital cardiac
arrest risk
In both registries, covariates were assessed using cardiovascular drugs,
drugs used for diabetes mellitus (used within 6 months before index date,










































..listed in Table 1), and use (index-date within prescription duration) of
Vaughan-Williams Class 1 or 3 antiarrhythmic drugs and/or common
(>_1000 users/year) non-cardiac QT-prolonging drugs.26 In DANCAR,
covariates associated with OHCA risk were assessed using additional
comorbidity information from diagnosis codes of hospital admissions up
to 10 years before OHCA.
Cellular electrophysiologic studies
The current generated by L-type calcium-channels (ICa,L) and action
potentials (APs) were measured in individual hiPSC-CMs, prepared as
described previously.27 Electrophysiologic measurements at 36± 0.2C
were performed 7–9 days after plating. ICa,L was measured in response to
depolarizing voltage clamp steps from -70 to 0 mV using the ruptured
patch-clamp technique. Dose-response curves for nifedipine and amlodi-
pine were fitted to the Hill equation: Idrug/Icontrol=1/[1þ(dose/IC50)n],
where Idrug/Icontrol is normalized ICa,L, dose is bath concentration of the
drug, IC50 is dose required for 50% current block, and n is the Hill coeffi-
cient. APs were measured in spontaneously beating hiPSC-CMs using the
amphotericin-B-perforated patch-clamp technique. AP parameters ana-
lysed included: maximum diastolic potential, maximum AP-amplitude
(APAmax), AP-duration at 20%, 50%, and 90% repolarization (APD20,
APD50, and APD90), maximal upstroke velocity (Vmax), and plateau ampli-
tude (APAplateau). Averages were taken from 10 consecutive APs. The
effects of nifedipine and amlodipine on ICa,L were tested at steady-state
(5 min after bath application), with increasing concentrations within one
cell. More details are provided in Supplementary material online,
Methods.
Statistical analysis
The v2 test was used to compare baseline characteristics between cases
and controls, and between the various covariates of study drug users.
The Mann–Whitney test was used to compare age between cases and
controls. We used conditional logistic regression to determine associa-
tions between exposure of interest and OHCA risk, applying two mod-
els. In Model 1, crude odd ratios (ORcrude) were calculated. In Model 2,
the OR was adjusted (ORadj) for all confounders that were univariately
significantly associated with OHCA and sufficiently powered (>5
exposed cases). Next, we performed stratified analyses regarding nitrate
use (as proxy for IHD), beta-blocker use and history of IHD and/or previ-
ous acute myocardial infarction (AMI, only in DANCAR) and calculated
Pinteraction using multivariable conditional logistic regression. Subgroup
analysis were performed in subsets of patients classified by the presence
of cardiovascular disease (in ARREST: defined as the use of any cardiovas-
cular drugs listed in Table 1; in DANCAR: defined as patients who had a
hospital contact for >_1 cardiovascular disease up to 10 years before
OHCA or the use of any cardiovascular drugs listed in Table 1). Paired
and unpaired t-tests were used to test the effects of drugs and between
drugs, respectively, on ICa,L and APs. We considered a two-sided P-value




Table 1 Baseline characteristics of cases and controls
ARREST DANCAR
Cases Controls P-value Cases Controls P-value
Total 2503 10 543 8101 40 505
Age (years), median (interquartile range) 67.0 (57.0–77.0) 66.0 (57.0–76.0) NA 68 (58–77) 68 (58–77) NA
Male sex 1938 (77.4) 8167 (77.5) NA 6435 (79.4) 32 175 (79.4) NA
Concomitant drug use
Beta-blockers 855 (34.2) 2338 (22.2) <0.001 1948 (24.1) 5330 (13.2) <0.001
Renin-angiotensin system inhibitors 1007 (40.2) 2778 (26.3) <0.001 3339 (41.2) 9351 (23.1) <0.001
Diuretics 890 (35.6) 2356 (22.3) <0.001 3695 (45.6) 10 279 (25.4) <0.001
Nitrates 358 (14.3) 574 (5.4) <0.001 977 (12.1) 1343 (3.3) <0.001
Statins 831 (33.2) 2613 (24.8) <0.001 5649 (30.8) 7615 (18.8) <0.001
Antithrombotics 1090 (43.5) 3004 (28.5) <0.001 3713 (45.8) 10 136 (25.0) <0.001
Non-dihyrdopyridine calcium antagonists 102 (4.1) 260 (2.5) <0.001 397 (4.9) 824 (2.0) <0.001
Antidiabetics 399 (15.9) 1135 (10.8) <0.001 1034 (12.8) 2882 (7.1) <0.001
Antiarrhythmic drugs class 1 and 3 54 (2.2) 41 (0.4) <0.001 117 (1.4) 216 (0.5) <0.001
Non-antiarrhythmic QT-prolonging drugs 133 (5.3) 331 (3.1) <0.001 619 (7.6) 2597 (6.4) <0.001
Comorbidities
Peripheral vascular disease 808 (10.0) 1640 (4.1) <0.001
Cerebral vascular disease 957 (11.8) 3064 (7.6) <0.001
Ischaemic heart disease (including previous AMI) 2511 (31.0) 4609 (11.4) <0.001
Atrial fibrillation 1440 (17.8) 2561 (6.3) <0.001
Congestive heart failure 1718 (21.2) 1708 (4.2) <0.001
Chronic kidney disease 384 (4.7) 799 (2.0) <0.001
Chronic obstructive pulmonary disease 643 (7.9) 1721 (4.3) <0.001
Numbers are expressed as n (%) unless indicated otherwise.
AMI, acute myocardial infarction; NA, not applicable.















































In ARREST, from a total of 3661 OHCA cases with cardiac causes
and documented VT/VF, complete medication histories were
obtained in 2503; these cases (median age 67.0 years, 77.4% male)
were matched to 10 543 controls (Figure 1). In DANCAR, 8101
OHCA cases (median age 68.0 years, 79.4% male), were matched to
40 505 controls (Figure 1). In both registries, use of all studied drug
categories and comorbidities (in DANCAR) was more prevalent
among cases than controls (Table 1).
Dihydropyridine use and out-of-hospital
cardiac arrest risk
In ARREST, current use of any dihydropyridine was not associated
with higher OHCA risk than no use of dihydropyridines [ORadj 0.84
(0.71–0.99), Figure 2]. Increased OHCA risk occurred among current
users of nifedipine compared to no use of dihydropyridines [ORadj
1.28 (1.003–1.63), Figure 2] and was dose-dependent [low-dose
ORadj 1.15 (0.84–1.59), high-dose ORadj 1.45 (1.02–2.07)]. In con-
trast, current use of amlodipine was associated with lower OHCA
risk than no use of dihydropyridines [ORadj 0.63 (0.50–0.79)], but this
lower OHCA risk was not dose-dependent [low-dose ORadj 0.57
(0.43–0.77), high-dose ORadj 0.70 (0.50–0.97)]. Accordingly, current
use of nifedipine was associated with higher OHCA risk than current
use of amlodipine [any-dose ORadj 2.03 (1.48–2.78), high-dose ORadj
2.31 (1.54–3.47), Figure 3]. In DANCAR, these key findings were simi-
lar: current use of high-dose nifedipine was associated with higher
OHCA risk than no use of dihydropyridines [ORadj 1.96 (1.18–3.25),
Figure 2] or current use of amlodipine [ORadj 2.20 (1.32–3.67),
Figure 3], while current use of amlodipine was associated with lower
OHCA risk than no use of dihydropyridines [ORadj 0.89 (0.82–0.97),
Figure 2]. ORcrude is provided in Supplementary material online,
Table S1.
To assess possible confounding, we studied whether concomitant
medication use was different between nifedipine users and amlodi-
pine users (Supplementary material online, Table S2). In both regis-
tries, there were no statistically significant differences. In DANCAR,
there were also no statistically significant differences in comorbidities
between nifedipine users and amlodipine users. In both registries, we
found no statistically significant differences in concomitant medication
use and comorbidities (in DANCAR) between low-dose and high-
dose nifedipine users (Supplementary material online, Table S3).
Moreover, in our subgroup analysis of patients with known cardio-
vascular disease, use of high-dose nifedipine was consistently associ-
ated with increased OHCA risk in both registries (Supplementary
material online, Table S4).
We next studied whether OHCA risk was further increased in
patients using nitrates (as proxy for IHD) by performing stratified
Figure 1 Flowchart of inclusion of out-of-hospital cardiac arrest cases. (A) ARREST registry. (B) DANCAR registry. CPR, cardiopulmonary resusci-
tation; OHCA, out-of-hospital cardiac arrest; VT/VF, ventricular tachycardia/ventricular fibrillation.

































analyses. We found that OHCA risk was not further increased in
patients using nitrates (ARREST: any-dose nifedipine Pinteraction 0.098,
high-dose nifedipine Pinteraction 0.050; DANCAR: any-dose nifedipine
Pinteraction 0.546; high-dose nifedipine Pinteraction 0.857, Supplementary
material online, Figure S1). Next, in DANCAR, we performed strati-
fied analyses according to IHD or previous AMI status. We found
that OHCA risk associated with any-dose nifedipine was not further
increased in this group (DANCAR: any-dose nifedipine Pinteraction
0.079, high-dose nifedipine Pinteraction 0.949).
To study whether increased OHCA risk of nifedipine may be
related to the effects of increased sympathetic stimulation, we con-
ducted stratified analysis according to concomitant use of beta-
blockers (which attenuate the effects of sympathetic stimulation).
We found that OHCA risk associated with nifedipine was not altered
in patients using beta-blockers (ARREST: any-dose nifedipine
Pinteraction 0.405, high-dose nifedipine Pinteraction 0.226; DANCAR:
any-dose nifedipine Pinteraction 0.766; high-dose nifedipine Pinteraction
0.796, Supplementary material online, Figure S1). Moreover, most ni-
fedipine users among cases used its slow-release form (ARREST:
N = 106 of 109, DANCAR: N = 55 of 58) which causes less sympa-
thetic stimulation than short-acting nifedipine,28 and there were no
cases who used high-dose short-acting nifedipine.
Cellular electrophysiologic studies
We studied whether the disparate associations between nifedipine
or amlodipine use and OHCA risk could be explained by differences
in cardiac electrophysiologic properties between both drugs. First,
we studied the effects of nifedipine and amlodipine on ICa,L. Figure 4A
shows typical total ICa,L recordings in the absence and presence of
various nifedipine and amlodipine concentrations. Dose-response
relationships of nifedipine and amlodipine (Figure 4B) were virtually
overlapping [IC50 104 ± 13 nmol/L (nifedipine, n = 5) vs.
64 ± 30 nmol/L (amlodipine, n = 5), P = 0.22; Hill coefficients
Figure 2 Current use of dihydropyridines, nifedipine, or amlodipine and out-of-hospital cardiac arrest risk compared with no use of any dihydro-
pyridine. Numbers in table are n (%) unless indicated otherwise. Error bars denote 95% confidence interval. In ARREST, dose information was un-
available for one case and two controls; these individuals were not included in the Figure. CI, confidence interval; DHP, dihydropyridine.
Figure 3 Current use of nifedipine and out-of-hospital cardiac arrest risk compared with current use of amlodipine. Numbers in table are n (%) un-
less indicated otherwise. Error bars denote 95% confidence interval. CI, confidence interval; OR, odds ratio.







































..0.66± 0.11 (nifedipine, n = 5) vs. 0.53 ± 0.05 (amlodipine, n = 5),
P = 0.25]. Next, we tested the effects on APs of 150 nM nifedipine
and 50 nM amlodipine (corresponding to maximal plasma concentra-
tions of 60 mg/day nifedipine and 10 mg/day amlodipine, respective-
ly29,30). Figure 4C shows typical APs, average effects are summarized
in Figure 4D. Both drugs caused reversible AP-shortening and de-
crease of APAmax and APAplateau (Figure 4C and D), but these effects
were larger for nifedipine (Figure 4D). For example, APD90 was
reduced by 21.6 ± 2.5 and 12.7± 1.8% for nifedipine and amlodipine,
respectively (P = 0.006).
Discussion
In this observational study with real-world data from two large inde-
pendent population-based OHCA registries in different countries,
high-dose nifedipine, but not low-dose nifedipine or any-dose amlodi-
pine, was associated with increased OHCA risk, independent of con-
comitant medication use or comorbidities. OHCA risk was not
further increased in the presence of IHD. Furthermore, at clinically
used concentrations, nifedipine caused more L-type calcium current
block, resulting in more action potential shortening.
Previous studies have raised serious concerns about the long-term
safety of L-type calcium-channel blockers, mainly short-acting dihy-
dropyridines.15,31 Increased AMI risk upon use of high-dose short-
acting calcium-channel blockers was reported among hypertension
patients.31 Also, increased total mortality risk was found among IHD
patients using high-dose short-acting nifedipine.15 One hypothesized
mechanism for these findings is increased sympathetic tone,15 most
pronounced for short-acting nifedipine.28 While reflex sympathetic
activation during nifedipine use may have occurred secondary to
rapid blood pressure drop among nifedipine users, we found that
increased VT/VF risk still occurred among nifedipine users who con-
comitantly used beta-blockers (Supplementary material online, Figure
S1); the latter drugs would block the effects of reflex sympathetic ac-
tivation. Also, the vast majority of nifedipine users used its slow-
release form; this form acts slowly and gradually, thereby not provok-
ing rapid blood pressure drop and reflex stimulation of the sympa-
thetic system. Supporting this notion, multiple randomized
controlled trials were conducted to study the association between
long-acting nifedipine and mortality risk,32–35 but none found
increased risk of (all-cause) mortality. Finally, the presence of coron-
ary steal by collateral arteries has been described during nifedipine
use,36 but the results seem to be inconsistent.37 For instance, one
Figure 4 Effects of nifedipine and amlodipine on the L-type calcium current (ICa,L) and action potentials.(A) Typical ICa,L recordings in absence and
presence of nifedipine (top) and amlodipine (bottom). Inset: voltage clamp protocol. (B) Average dose-response curves of nifedipine and amlodipine
on ICa,L. Note that currents are normalized to current before drug application. Solid lines: Hill equation fits of average data. (C) Typical examples of
APs in absence and presence of 150 nM nifedipine (top) and 50 nM amlodipine (bottom). Both drugs caused reversible AP-shortening. (D) Average
effects of nifedipine (150 nM) and amlodipine (50 nM) on AP-properties. *P < 0.05 control conditions vs. drugs; #P < 0.05 nifedipine vs. amlodipine.



























































































..study reported pro-ischaemic effects of nifedipine in chronic stable
angina patients with good collateral flow and suggested that these
findings could be mediated through coronary steal.36 However, an-
other study found opposite effects of nifedipine administration.37
Also, while increased AMI risk was reported among users of short-
acting calcium blockers,31 multiple randomized controlled trials
found no evidence for increased AMI risk among users of long-acting
calcium channel antagonists, while the vast majority of nifedipine
users among the OHCA cases in our study used its slow-release
form. Our study indicates no further increased OHCA risk among
patients with IHD. To our knowledge, no studies yet have investi-
gated whether long-acting dihydropyridine use is associated with
increased OHCA risk. Such studies require a dedicated study design,
in particular, to ascertain that OHCA resulted from cardiac arrhyth-
mia (VT/VF) rather than from non-cardiac causes. Thus, ECG docu-
mentation of VT/VF during OHCA is required, but this is extremely
challenging, because OHCA occurs suddenly and unexpectedly, and
VF dissolves into asystole within minutes if left untreated. The often-
used pragmatic definition of OHCA (without requirement of ECG
documentation) of the European Society of Cardiology (‘event
occurring within 1 h of symptom onset or, if unwitnessed, within 24 h
of the victim being seen in good health’38) carries the risk of misclassi-
fication of non-cardiac causes. This is particularly relevant in our
study, since hypertension patients (some of whom are treated
with dihydropyridines) have increased risk of these non-cardiac
causes (stroke, ruptured aneurysm). To overcome these difficulties,
and to comprehensively study risk factors associated with
OHCA, we set-up dedicated population-based OHCA registries
(ARREST, DANCAR) and the ESCAPE-NET research network.16
These efforts now allow us to study more reliably the risk of OHCA
from cardiac arrhythmia associated with dihydropyridine use.
Our findings indicate that increased OHCA risk of high-dose ni-
fedipine may be related to specific drug effects, rather than a class
effect. While we found no evidence in our epidemiologic studies
that increased sympathetic stimulation is involved, our cellular
electrophysiologic studies provided possible clues. Different
dihydropyridines have distinct potencies to inhibit L-type calcium-
channels in vascular smooth muscle cells or myocardium. For ex-
ample, nifedipine has 10 times higher affinity for vascular cells
than myocardium.39 Although nifedipine and amlodipine are pre-
scribed because of their effects on vascular L-type calcium-
channels, we found that both drugs significantly block cardiac ICa,L,
thereby shortening AP-duration. AP-shortening may provoke VT/
VF by facilitating re-entrant excitation, the predominant
electrophysiologic mechanism of VT/VF. This is most clearly dem-
onstrated by the rare inherited Short-QT-syndrome, which is
associated with a high risk of OHCA.40 Conversely, AP-
prolongation is the mechanism by which Classes IA and III antiar-
rhythmic drugs exert their therapeutic action. Thus, AP-shortening
may contribute to the increase in OHCA risk of high-dose nifedi-
pine. This may also explain why high-dose nifedipine, but not low-
dose nifedipine or amlodipine, is associated with increased OHCA
risk: high-dose nifedipine causes more AP-shortening than both
other conditions. Of note, although amlodipine blocks cardiac
L-type calcium-channels at similar concentrations as nifedipine, the
extent of ICa,L block in clinical practice is lower for amlodipine than
for nifedipine, because prescribed dosages (and plasma-
concentrations) are significantly lower for amlodipine.
Our findings provide clues for the design of preventive strategies
against this adverse drug effect of nifedipine. Most strategies against
OHCA risk of drugs that impact on cardiac electrophysiology focus
strongly on identifying vulnerable individuals, e.g. individuals with
(genetic) vulnerability to excessive QT-prolongation when prescrip-
tion of QT-prolonging medication is considered. Similarly, guidelines
state that anti-arrhythmic sodium-channel blockers such as flecainide
should be withheld from patients with acquired causes of reduced
cardiac excitability, e.g. cardiac ischaemia and/or heart failure. In the
case of nifedipine, the strategy may have to focus both on identifying
vulnerable individuals and on limiting the height of prescribed dos-
ages. Although dose-dependent reduction in blood pressure was
shown in patients with hypertension41 and high-dose nifedipine was
shown to better attenuate angina pectoris than low-dose nifedi-
pine,42 the dose-effect relationships of nifedipine strongly differ be-
tween patients.43 Careful titration of nifedipine dose may have to be
considered. Clearly, future studies are required to establish (i)
whether nifedipine use confers higher OHCA risk than amlodipine
use, (ii) whether vulnerable individuals are those who receive nifedi-
pine for hypertension treatment, and (iii) whether lower dosages im-
pact less on cardiac electrophysiology and OHCA risk, while
retaining their beneficial effects on treatment for IHD and/or
hypertension.
Strengths and limitations
A major strength of the ARREST and DANCAR registries is that
documentation of VT/VF was present; this reduces risk of misclassifi-
cation of patients who suffered OHCA from non-cardiac causes.
Also, the population-based real-world design minimized selection
bias by prospectively including every OHCA case in large contiguous
regions representative for the community at large. Finally, our cellular
electrophysiologic studies supported these epidemiologic findings by
revealing differential effects on the AP that may explain these findings.
The observational nature of our epidemiologic studies comes with
inherent limitations, e.g. the fact that we could only detect associa-
tions without proving causality. To gain more insight into a possible
mechanistic explanation, we conducted cellular electrophysiologic
studies using hiPSC-CMs. Although hiPSC-CMs are relatively imma-
ture compared to cardiomyocytes from an adult heart,44 ICa,L antago-
nists have similar effects in hiPSC-CMs to those observed in native
cardiomyocytes.45 Another limitation is the lack of completeness of
data from the Dutch cohort since almost one-third of the OHCA
cases was not included primarily due to lack of medication history
(Figure 1). However, we expect that incomplete data were distrib-
uted proportionally between users and non-users of nifedipine. Also,
while nifedipine was used by 38% of dihydropyridine users in the
Netherlands, this was only the case in 4% in Denmark. As a conse-
quence, we were able to identify only 27 users of high-dose nifedipine
at the time of OHCA in the Danish registry, which is also reflected in
the wide CI (Figure 2). Another limitation is that, although drug-
dispensing data were complete, we had no information whether
claimed medications were actually taken in both cohorts. In any case,
drug-dispensing records, used in both cohorts, are already one im-
portant step closer to actual intake than drug prescription records.




























































































..Furthermore, we have no reason to assume that intake behaviour be-
tween nifedipine and amlodipine users would be different. Yet, pos-
sible misclassification arising from this was probably similarly
distributed between cases and controls. To mitigate the limitations
associated with use of medication proxies, we also used information
on comorbidities in our multivariable analyses using DANCAR-data.
This approach resulted in similar findings. Finally, there may have
been confounding by indication, as cases and controls are different
regarding concomitant drug use (Table 1), pointing towards cases in
general having more comorbidity. However, it was very hard—if not
practically impossible—to obtain data to prove that possible con-
founding was present or absent. We addressed this problem primar-
ily by comparing OHCA risk of nifedipine use with amlodipine use.
Moreover, we found no evidence that nifedipine users differed signifi-
cantly from amlodipine users in demographic variables or their
comorbidities (Supplementary material online, Table S2). In addition,
the robustness of our findings regarding high-dose nifedipine was
confirmed by a subgroup analysis in which we examined only patients
with cardiovascular disease (Supplementary material online, Table
S4). However, it is still possible that (unmeasured) residual confound-
ers might have affected our observed associations.
Conclusion
High-dose nifedipine, but not low-dose nifedipine or any-dose of
amlodipine, is associated with increased OHCA risk in the general
population. Differences in cellular electrophysiologic properties of
clinically used concentrations between both drugs were found.
Supplementary material
Supplementary material is available at European Heart Journal –
Cardiovascular Pharmacotherapy online.
Acknowledgements
The authors greatly appreciate the contributions of Paulien Homma,
Remy Stieglis, and Sandra de Haas for data management of the
ARREST registry, and are greatly indebted to all participating EMS dis-
patch centres (Amsterdam, Haarlem, and Alkmaar), regional ambu-
lance services (Ambulance Amsterdam, GGD Kennemerland, Witte
Kruis, and Veiligheidsregio Noord-Holland Noord Ambulancezorg),
fire brigades, and police departments in the study region for their
contribution and support. The authors would also like to thank the
pharmacists, PHARMO Database Network and Stichting
Farmaceutische Kerngetallen. For completion of the case reports
which form the Danish Cardiac Arrest Registry, the authors thank
the Danish Emergency Medical Services.
Funding
This work was supported by the European Union’s Horizon 2020 re-
search and innovation programme under the acronym ESCAPE-NET, reg-
istered under grant agreement No 733381 (T.E.E., M.T.B., and H.L.T.) and
the Netherlands CardioVascular Research Initiative (Dutch Heart
Foundation, Dutch Federation of University Medical Centers,
Netherlands Organization for Health Research and Development, and
Royal Netherlands Academy of Sciences) grant CVON-2018-30 Predict 2
(M.T.B. and H.L.T.). The Danish Cardiac Arrest Registry is supported by
Trygfonden. Work by L.v.d.B. and R.P.D. was supported by a European
Research Council Starting Grant (STEMCARDIORISK; grant agreement
#638030), and a VIDI fellowship from the Netherlands Organisation for
Scientific Research (ILLUMINATE; grant agreement #91715303).
Conflict of interest: G.H.G. was supported by an unrestricted clinical
research scholarship from the Novo Nordisk Foundation. C.T.-P. reports
grants and personal fees from Bayer and grants from Biotronic. And all
other authors have no conflict of interest to declare.
References
1. Myerburg RJ, Castellanos A. Cardiac arrest and sudden cardiac death. In: P Libby,
RO Bonow, DL Mann, DP, Zipes eds. Braunwald’s Heart Disease: A Textbook of
Cardiovascular Medicine. Oxford, UK: Elsevier 2007 pp. 933–974.
2. Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhyth-
mias. N Engl J Med 2001;345:1473–1482.
3. Bardai A, Amin AS, Blom MT, Bezzina CR, Berdowski J, Langendijk PNJ, Beekman
L, Klemens CA, Souverein PC, Koster RW, de Boer A, Tan HL. Sudden cardiac
arrest associated with use of a non-cardiac drug that reduces cardiac
excitability: evidence from bench, bedside, and community. Eur Heart J 2013;34:
1506–1516.
4. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;
350:1013–1022.
5. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs
and the risk of sudden cardiac death. N Engl J Med 2009;360:225–235.
6. Straus SMJM, Sturkenboom MCJM, Bleumink GS, Dieleman JP, van der Lei J, de
Graeff PA, Kingma JH, Stricker BHC. Non-cardiac QTc-prolonging drugs and the
risk of sudden cardiac death. Eur Heart J 2005;26:2007–2012.
7. Cheng Y-J, Nie X-Y, Chen X-M, Lin X-X, Tang K, Zeng W-T, Mei W-Y, Liu L-J,
Long M, Yao F-J, Liu J, Liao X-X, Du Z-M, Dong Y-G, Ma H, Xiao H-P, Wu S-H.
The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll
Cardiol 2015;66:2173–2184.
8. Weeke P, Jensen A, Folke F. Antipsychotics and associated risk of out-of-hospital
cardiac arrest. Clin Pharmacol Ther 2014;96:490–497.
9. Weeke P, Jensen A, Folke F, Gislason GH, Olesen JB, Andersson C, Fosbøl EL,
Larsen JK, Lippert FK, Nielsen SL, Gerds T, Andersen PK, Kanters JK, Poulsen
HE, Pehrson S, Køber L, Torp-Pedersen C. Antidepressant use and risk of out-
of-hospital cardiac arrest: a nationwide case–time–control study. Clin Pharmacol
Ther 2012;92:72–79.
10. Risgaard B, Winkel BG, Jabbari R, Lynge TH, Wissenberg M, Glinge C, Haunsø S,
Behr ER, Fink-Jensen A, Gislason GH, Tfelt-Hansen J. Sudden cardiac death:
pharmacotherapy and proarrhythmic drugs: a Nationwide Cohort Study in
Denmark. JACC: Clin Electrophysiol 2017;3:473–481.
11. Postema PG, Wolpert C, Amin AS, Probst V, Borggrefe M, Roden DM, Priori
SG, Tan HL, Hiraoka M, Brugada J, Wilde AAM. Drugs and Brugada syndrome
patients: review of the literature, recommendations and an up-to-date website
(www.brugadadrugs.org). Heart Rhythm 2009;6:1335–1341.
12. Bardai A, Blom MT, van Noord C, Verhamme KM, Sturkenboom M, Tan HL.
Sudden cardiac death is associated both with epilepsy and with use of antiepilep-
tic medications. Heart 2015;101:17–22.
13. Wu J, Wang X, Chung YY, Koh CH, Liu Z, Guo H, Yuan Q, Wang C, Su S, Wei
H. L-type calcium channel inhibition contributes to the proarrhythmic effects of
aconitine in human cardiomyocytes. PLoS One 2017;12:e0168435.
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